Form 4 Filing for Hepion Pharmaceuticals, Inc.

Michael Purcell, a director at Hepion Pharmaceuticals, Inc., reported a transaction on April 21, 2026. He acquired 1,250,000 shares of common stock at a price of $0.04 per share. Following this transaction, Mr. Purcell directly owns 1,250,000 shares of the company's common stock. The filing indicates this was a purchase transaction.